| Name: | Dexamethasone EP Impurity H |
| Catalogue No. | VL273024 |
| CAS No. | 10106-41-9 |
| Molecular Formula | C24H30O5 |
| Molecular Weight | 398.5 |
| Status | In-stock |
| IUPAC Name | 2-((8S,10S,13S,14S,16R,17R)-17-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate |
| Description | Dexamethasone EP Impurity H (CAS No.: 10106-41-9) or 2-((8S,10S,13S,14S,16R,17R)-17-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate is an impurity of Dexamethasone. Early administration of dexamethasone can help to diminish the duration of mechanical ventilation and mortality in patients having moderate-to-severe ARDS. |
| References | Dongala, Thirupathi, et al. “Stability Indicating LC Method Development for Hydroxychloroquine Sulfate Impurities as Available for Treatment of COVID-19 and Evaluation of Risk Assessment prior to Method Validation by Quality by Design Approach.” Chromatographia, vol. 83, no. 10, Aug. 2020, pp. 1269–81,https://doi.org/10.1007/s10337-020-03945-5.Villar, Jesús, et al. “Dexamethasone Treatment for the Acute Respiratory Distress Syndrome: A Multicentre, Randomised Controlled Trial.” The Lancet Respi |
![(16α)-21-[(Ethoxycarbonyl)oxy]-17-hydroxy-16-methylpregna-1,4,9(11)-triene-3,20-dione](/public/site/files/site_images/thumb_16alpha-21-ethoxycarbonyl-oxy-17-hydroxy-16-methylpregna-1-4-9-11-triene-3-20-dione47031.png)
